Baader Bank Aktiengesellschaft Purchases Shares of 28,000 Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Baader Bank Aktiengesellschaft acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 28,000 shares of the company’s stock, valued at approximately $373,000.

A number of other institutional investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the third quarter valued at approximately $54,000. Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC boosted its position in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares in the last quarter. Finally, Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals in the third quarter worth $1,431,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. B. Riley started coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 target price on the stock. HC Wainwright boosted their price objective on Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Craig Hallum raised their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th.

Eton Pharmaceuticals Price Performance

ETON stock opened at $17.32 on Friday. The company has a market capitalization of $451.19 million, a PE ratio of -78.73 and a beta of 1.38. Eton Pharmaceuticals, Inc. has a 12 month low of $3.03 and a 12 month high of $17.77. The firm’s 50-day moving average is $13.37 and its 200 day moving average is $8.59.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.